Systolic blood pressure time in target range and long-term outcomes in patients with ischemic cardiomyopathy

医学 内科学 心脏病学 血压 缺血性心肌病 心肌病 期限(时间) 心力衰竭 射血分数 物理 量子力学
作者
Guangguo Fu,Zhuoming Zhou,Bohao Jian,Suiqing Huang,Zicong Feng,Mengya Liang,Quan Liu,Yang Huang,Kaizheng Liu,Guangxian Chen,Zhongkai Wu
出处
期刊:American Heart Journal [Elsevier]
卷期号:258: 177-185 被引量:12
标识
DOI:10.1016/j.ahj.2022.12.011
摘要

The relationship between the degree of systolic blood pressure (SBP) control and outcomes remains unclear in patients with ischemic cardiomyopathy (ICM). Current control metrics may not take into account the potential effects of SBP fluctuations over time on patients.This study was a post-hoc analysis of the surgical treatment of ischemic heart failure trial which enrolled 2,136 participants with ICM. Our SBP target range was defined as 110 to 130 mm Hg and the time in target range (TTR) was calculated by linear interpolation.A total of 1,194 patients were included. Compared with the quartile 4 group (TTR 77.87%-100%), the adjusted hazard ratios and 95% confidence intervals of all-cause mortality were 1.32 (0.98-1.78) for quartile 3 group (TTR 54.81%-77.63%), 1.40 (1.03-1.90) for quartile 2 group (TTR 32.59%-54.67%), and 1.53 (1.14-2.04) for quartile 1 group (TTR 0%-32.56%). Per 29.28% (1-SD) decrement in TTR significantly increased the risk of all-cause mortality (1.15 [1.04-1.26]). Similar results were observed in the cardiovascular (CV) mortality and the composite outcome of all-cause mortality plus CV rehospitalization, and in the subgroup analyses of either coronary artery bypass grafting or medical therapy, and different baseline SBP.In patients with ICM, the higher TTR was significantly associated with decreased risk of all-cause mortality, CV mortality and the composite outcome of all-cause mortality plus CV rehospitalization, regardless of whether the patient received coronary artery bypass grafting or medical therapy, and the level of baseline SBP. TTR may be a surrogate metric of long-term SBP control in patients with ICM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冷颖完成签到,获得积分10
1秒前
Mira完成签到,获得积分10
1秒前
LYSM应助刘夕采纳,获得10
2秒前
所所应助乾巧采纳,获得10
2秒前
123发布了新的文献求助10
2秒前
Ming完成签到,获得积分10
3秒前
lyt完成签到,获得积分10
3秒前
sherrymasha完成签到,获得积分10
4秒前
王小雨完成签到 ,获得积分10
6秒前
6秒前
科研通AI6应助科研龙采纳,获得10
6秒前
耍酷问兰发布了新的文献求助10
6秒前
万能图书馆应助QLLW采纳,获得10
6秒前
无限大门完成签到,获得积分10
7秒前
pqq完成签到,获得积分10
8秒前
北风语完成签到,获得积分10
8秒前
贝贝贝完成签到,获得积分10
9秒前
大个应助高铭泽采纳,获得10
9秒前
cc完成签到,获得积分20
10秒前
西瓜二郎发布了新的文献求助10
11秒前
12秒前
12秒前
elang发布了新的文献求助10
14秒前
丹丹完成签到 ,获得积分10
14秒前
14秒前
14秒前
cc发布了新的文献求助10
14秒前
yang完成签到,获得积分20
15秒前
ad发布了新的文献求助10
15秒前
16秒前
浮游应助科研通管家采纳,获得10
16秒前
BOb完成签到 ,获得积分10
16秒前
嘿嘿应助科研通管家采纳,获得10
16秒前
嘿嘿应助科研通管家采纳,获得10
17秒前
浮游应助科研通管家采纳,获得10
17秒前
桐桐应助科研通管家采纳,获得10
17秒前
浮游应助科研通管家采纳,获得10
17秒前
标致天思应助科研通管家采纳,获得10
17秒前
桐桐应助科研通管家采纳,获得10
17秒前
脑洞疼应助科研通管家采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Binary Alloy Phase Diagrams, 2nd Edition 8000
Comprehensive Methanol Science Production, Applications, and Emerging Technologies 2000
From Victimization to Aggression 1000
Translanguaging in Action in English-Medium Classrooms: A Resource Book for Teachers 700
Exosomes Pipeline Insight, 2025 500
Red Book: 2024–2027 Report of the Committee on Infectious Diseases 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5653351
求助须知:如何正确求助?哪些是违规求助? 4789770
关于积分的说明 15063822
捐赠科研通 4811874
什么是DOI,文献DOI怎么找? 2574163
邀请新用户注册赠送积分活动 1529858
关于科研通互助平台的介绍 1488577